BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35961847)

  • 1. Longitudinal GFR trends after neoadjuvant chemotherapy prior to nephroureterectomy for upper tract urothelial carcinoma.
    Labbate CV; Hensley PJ; Miest TS; Qiao W; Adibi M; Shah AY; Chery L; Papadopoulos J; Siefker-Radtke AO; Gao J; Guo CC; Czerniak BA; Navai N; Kamat AM; Dinney CP; Campbell MT; Matin SF
    Urol Oncol; 2022 Oct; 40(10):454.e17-454.e23. PubMed ID: 35961847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of contralateral kidney volume on renal function after radical nephroureterectomy: Implications for eligibility for neoadjuvant chemotherapy for upper tract urothelial cancer.
    Song W; Sung HH; Han DH; Jeong BC; Seo SI; Jeon SS; Lee HM; Choi HY; Jeon HG
    Urol Oncol; 2017 Mar; 35(3):114.e1-114.e7. PubMed ID: 27908680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does neoadjuvant chemotherapy have therapeutic benefit for node-positive upper tract urothelial carcinoma? Results of a multi-center cohort study.
    Shigeta K; Matsumoto K; Ogihara K; Murakami T; Anno T; Umeda K; Izawa M; Baba Y; Sanjo T; Shojo K; Tanaka N; Takeda T; Morita S; Kosaka T; Mizuno R; Arita Y; Akita H; Jinzaki M; Kikuchi E; Oya M
    Urol Oncol; 2022 Mar; 40(3):105.e19-105.e26. PubMed ID: 34454822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in the use of neoadjuvant chemotherapy and oncological outcomes for high-risk upper tract urothelial carcinoma: a multicentre retrospective study.
    Hamaya T; Hatakeyama S; Tanaka T; Kubota Y; Togashi K; Hosogoe S; Fujita N; Kusaka A; Tokui N; Okamoto T; Yamamoto H; Yoneyama T; Yoneyama T; Hashimoto Y; Ohyama C
    BJU Int; 2021 Oct; 128(4):468-476. PubMed ID: 33484231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy.
    Xylinas E; Rink M; Margulis V; Clozel T; Lee RK; Comploj E; Novara G; Raman JD; Lotan Y; Weizer A; Roupret M; Pycha A; Scherr DS; Seitz C; Ficarra V; Trinh QD; Karakiewicz PI; Montorsi F; Zerbib M; Shariat SF;
    BJU Int; 2013 Aug; 112(4):453-61. PubMed ID: 23464979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathologic stage as a surrogate for oncologic outcomes after receipt of neoadjuvant chemotherapy for high-grade upper tract urothelial carcinoma.
    Singla N; Christie A; Freifeld Y; Ghandour RA; Woldu SL; Clinton TN; Petros FG; Robyak H; Yeh HC; Fang D; Enikeev D; Bagrodia A; Sagalowsky AI; Lotan Y; Raman JD; Matin SF; Margulis V
    Urol Oncol; 2020 Dec; 38(12):933.e7-933.e12. PubMed ID: 32430254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review.
    Aziz A; Dobruch J; Hendricksen K; Kluth LA; Necchi A; Noon A; Rink M; Roghmann F; Seiler R; Gontero P; Kassouf W; Shariat SF; Xylinas E;
    World J Urol; 2017 Sep; 35(9):1401-1407. PubMed ID: 28074261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of perioperative chemotherapy for upper tract urothelial carcinoma patients treated with radical nephroureterectomy.
    Pinar U; Calleris G; Grobet-Jeandin E; Grande P; Benamran D; Thibault C; Gontero P; Rouprêt M; Seisen T
    World J Urol; 2023 Nov; 41(11):3205-3230. PubMed ID: 36905443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy.
    Leow JJ; Chong YL; Chang SL; Valderrama BP; Powles T; Bellmunt J
    Eur Urol; 2021 May; 79(5):635-654. PubMed ID: 32798146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contemporary Trends of Systemic Neoadjuvant and Adjuvant Intravesical Chemotherapy in Patients With Upper Tract Urothelial Carcinomas Undergoing Minimally Invasive or Open Radical Nephroureterectomy: Analysis of US Claims on Perioperative Outcomes and Health Care Costs.
    Del Giudice F; van Uem S; Li S; Vilson FL; Sciarra A; Salciccia S; Busetto GM; Maggi M; Tiberia L; Viscuso P; Canale V; Panebianco V; Pecoraro M; Ferro M; Moschini M; Krajewski W; D'Andrea D; Cacciamani GE; Mari A; Soria F; Porpiglia F; Fiori C; Amparore D; Checcucci E; Autorino R; De Berardinis E; Chung BI
    Clin Genitourin Cancer; 2022 Apr; 20(2):198.e1-198.e9. PubMed ID: 35031226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant Chemotherapy in Elderly Patients With Upper Tract Urothelial Cancer: Oncologic Outcomes From a Multicenter Study.
    Grossmann NC; Pradere B; D'Andrea D; Schuettfort VM; Mori K; Rajwa P; Quhal F; Laukhtina E; Katayama S; Fankhauser CD; Xylinas E; Margulis V; Moschini M; Abufaraj M; Bandini M; Lonati C; Nyirady P; Karakiewicz PI; Fajkovic H; Shariat SF
    Clin Genitourin Cancer; 2022 Jun; 20(3):227-236. PubMed ID: 35125303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy.
    Kaag MG; O'Malley RL; O'Malley P; Godoy G; Chen M; Smaldone MC; Hrebinko RL; Raman JD; Bochner B; Dalbagni G; Stifelman MD; Taneja SS; Huang WC
    Eur Urol; 2010 Oct; 58(4):581-7. PubMed ID: 20619530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant versus adjuvant chemotherapy for upper tract urothelial carcinoma.
    Martini A; Falagario UG; Waingankar N; Daza J; Treacy PJ; Necchi A; Galsky MD; Sfakianos JP
    Urol Oncol; 2020 Aug; 38(8):684.e9-684.e15. PubMed ID: 32284255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative predictors of renal function decline after radical nephroureterectomy for upper tract urothelial carcinoma.
    Kaag M; Trost L; Thompson RH; Favaretto R; Elliott V; Shariat SF; Maschino A; Vertosick E; Raman JD; Dalbagni G
    BJU Int; 2014 Nov; 114(5):674-9. PubMed ID: 24314050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Segmental ureterectomy vs. radical nephroureterectomy for ureteral carcinoma in patients with a preoperative glomerular filtration rate less than 90 ml/min/1.73 m
    Abrate A; Sessa F; Campi R; Preto M; Olivero A; Varca V; Benelli A; Sessa M; Sebastianelli A; Pavone C; Serretta V; Vella M; Brunocilla E; Serni S; Trombetta C; Terrone C; Gregori A; Lissiani A; Gontero P; Schiavina R; Gacci M; Simonato A
    Urol Oncol; 2020 Jun; 38(6):601.e11-601.e16. PubMed ID: 32273050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors associated with ineligibility of adjuvant cisplatin-based chemotherapy after nephroureterectomy.
    Shao IH; Lin YH; Hou CP; Juang HH; Chen CL; Chang PL; Tsui KH
    Drug Des Devel Ther; 2014; 8():1985-90. PubMed ID: 25364228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Pathological Stage in Patients Treated with and without Neoadjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma.
    Liao RS; Gupta M; Schwen ZR; Patel HD; Kates M; Johnson MH; Hahn NM; McConkey D; Bivalacqua TJ; Pierorazio PM
    J Urol; 2018 Jul; 200(1):68-73. PubMed ID: 29307680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive model for systemic recurrence following cisplatin-based neoadjuvant chemotherapy and radical nephroureterectomy for high risk upper tract urothelial carcinoma.
    Ghandour RA; Freifeld Y; Cheaib J; Singla N; Meng X; Kenigsberg A; Bagrodia A; Woldu S; Hoffman-Censits J; Enikeev D; Rapoport L; Petros FG; Raman JD; Pierorazio PM; Matin SF; Margulis V
    Urol Oncol; 2021 Nov; 39(11):788.e15-788.e21. PubMed ID: 34330655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncological Outcomes of Laparoscopic Nephroureterectomy Versus Open Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: An European Association of Urology Guidelines Systematic Review.
    Peyronnet B; Seisen T; Dominguez-Escrig JL; Bruins HM; Yuan CY; Lam T; Maclennan S; N'dow J; Babjuk M; Comperat E; Zigeuner R; Sylvester RJ; Burger M; Mostafid H; van Rhijn BWG; Gontero P; Palou J; Shariat SF; Roupret M
    Eur Urol Focus; 2019 Mar; 5(2):205-223. PubMed ID: 29154042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients With Diminished Renal Function.
    Koshkin VS; Barata PC; Rybicki LA; Zahoor H; Almassi N; Redden AM; Fergany AF; Kaouk J; Haber GP; Stephenson AJ; Ornstein MC; Gilligan T; Garcia JA; Rini BI; Grivas P
    Clin Genitourin Cancer; 2018 Aug; 16(4):e879-e892. PubMed ID: 29576445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.